Login / Signup

Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort.

Lydia C T BuerBjørn A MoumMilada CvancarovaDavid J WarrenNils BolstadAsle W MedhusMarte L Høivik
Published in: Scandinavian journal of gastroenterology (2019)
Improvement of biochemical markers of inflammation was observed in CD while clinical activity scores improved in UC patients. For CD, baseline CRP was correlated with lower concentrations of p-VDZ at week 14.
Keyphrases